US Patent No: 6,267,985

Number of patents in Portfolio can not be more than 2000

Clear oil-containing pharmaceutical compositions

6 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
LIPOCINE INC.SALT LAKE CITY, UT15

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Feng-Jing Salt Lake City, UT 36 2958
Patel, Mahesh V Salt Lake City, UT 82 3467

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
5,350,741 Enteric formulations of physiologically active peptides and proteins 90 1992
5,653,987 Liquid formulations for proteinic pharmaceuticals 77 1995
 
PHARMACIA & UPJOHN AB (2)
5,665,379 Lipid particle forming matrix, preparation and use thereof 33 1994
5,626,869 Pharmaceutical composition containing a defined lipid system 42 1995
 
American Pharmed Labs, Inc. (1)
* 5,120,710 Oral lipid medicinal composition 27 1990
 
NOVARTIS AG (3)
* 4,388,307 Galenical compositions 151 1982
* 5,342,625 Pharmaceutical compositions comprising cyclosporins 220 1992
5,589,455 Cyclosporin-containing soft capsule compositions 68 1995
 
PII DRUG DELIVERY, LLC (1)
5,532,002 Gelatin pharmaceutical formulations 49 1994
 
The United States of America as represented by the Secretary of Agriculture (1)
5,817,320 In ovo immunization of avian embryos with oil-emulsion vaccines 22 1996
 
MULLER, BERND W. (1)
* 4,719,239 Pharmaceutical multicomponent systems and method of preparing same 111 1985
 
BIOMOLECULAR PRODUCTS, INC. (1)
5,741,822 Mixed lipid-bicarbonate colloidal particles for delivering drugs 19 1994
 
MONTERESEARCH S.R.L. (1)
5,656,277 Nor- and homo- bile acids derivatives as absorption enhancers for medicaments 16 1994
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (1)
5,766,629 Oral cyclosporin formulations 54 1996
 
HEMAGEN/PFC (1)
5,616,330 Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same 45 1994
 
Hoffmann-La Roche Inc. (1)
5,747,066 Mixed micelles 23 1996
 
ZENECA LIMITED (1)
5,731,355 Pharmaceutical compositions of propofol and edetate 56 1997
 
INSTITUTE FOR ADVANCED SKIN RESEARCH, INC. (1)
5,948,825 Microemulsion preparation containing a slightly absorbable substance 11 1995
 
BRISTOL-MYERS SQUIBB COMPANY (1)
* 4,713,246 Etoposide oral dosage form 28 1986
 
HANMI PHARM. CO., LTD. (1)
5,639,474 Cyclosporin soft capsule composition 44 1995
 
BIOGLAN LABORATORIES LIMITED (1)
* 4,572,915 Clear micellized solutions of fat soluble essential nutrients 53 1984
 
RENTSCHLER ARZNEIMITTEL GMBH & CO. (1)
5,614,491 Liquid preparations containing cyclosporin and process for preparing same 54 1994
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (1)
5,686,105 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery 56 1995
 
California Biotechnology Inc. (1)
* 4,994,439 Transmembrane formulations for drug administration 126 1989
 
AAIPHARMA SERVICES CORP. (1)
* 5,206,219 Oral compositions of proteinaceous medicaments 185 1991
 
ISP CAPITAL, INC. (1)
* 5,300,529 Stable, clear, efficacious aqueous microemulsion compositions containing a high loading of a water-insoluble, agriculturally active chemical 18 1993
 
SANDOZ LTD. (1)
5,639,724 Cyclosporin galenic forms 87 1993
 
WATSON LABORATORIES, INC. (1)
5,858,401 Pharmaceutical composition for cyclosporines 82 1997
 
Patralan Limited (1)
5,656,289 Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase 47 1994
 
KABI PHARMACIA AB (1)
* 5,244,925 Emulsion for parenteral administration 23 1991
 
Sterling Drug Inc. (1)
* 5,145,684 Surface modified drug nanoparticles 643 1991
 
T.I.L. Medical Ltd. (1)
* 4,944,949 Pharmaceutical delivery systems 72 1987
 
R.P. SCHERER CORPORATION (4)
* 4,727,109 Pharmaceutical preparation with an active substance of low solubility in water and gastric juices 25 1985
* 5,071,643 Solvent system enhancing the solubility of pharmaceuticals for encapsulation 57 1987
5,376,688 Enhanced solubility pharmaceutical solutions 32 1992
5,645,856 Delivery systems for hydrophobic drugs 132 1995
 
BioNumerik Pharmaceuticals, Inc. (1)
5,726,181 Formulations and compositions of poorly water soluble camptothecin derivatives 47 1995
 
ATHENA NEUROSCIENCES, INC. (4)
5,444,041 Convertible microemulsion formulations 108 1992
5,633,226 Convertible microemulsion formulations 38 1995
5,646,109 Convertible microemulsion formulations 35 1995
5,707,648 Transparent liquid for encapsulated drug delivery 101 1995
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
5,364,632 Medicinal emulsions 111 1993
 
TROPONWERKE GMBH & CO. KG, A CORP. OF GERMANY (1)
* 4,731,384 Etofenamate formulation 23 1986
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (13)
* 7,338,971 Treatment of inflammatory, cancer, and thrombosis disorders 1 2001
* 2003/0045,562 Treatment of inflammatory, cancer, and thrombosis disorders 3 2001
7,374,772 Topical antifungal treatment 0 2002
* 2005/0096,296 Pharmaceutical compositions with synchronized solubilizer release 15 2004
* 2007/0082,016 Microemulsion preconcentrate comprising a renin inhibitor 2 2004
* 2006/0051,462 Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients 15 2005
* 2007/0014,820 Opioid formulations 4 2006
* 2008/0207,494 Cyclosporin Compositions 5 2006
* 2007/0004,668 Antisense permeation enhancers 4 2006
* 2007/0027,120 Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes 3 2006
* 2007/0003,614 Pharmaceutical compositions comprising active vitamin D compounds 6 2006
8,148,416 Treatment of inflammatory, cancer, and thrombosis disorders 7 2008
* 2010/0239,665 PHARMACEUTICAL NIMODIPINE COMPOSITIONS 6 2008
 
Pegsphere Co., Ltd. (1)
* 2003/0077,322 Solid dispersion system of pranlukast with improved dissolution and method for preparing the same 0 2002
 
TRANSFORM PHARMACEUTICALS, INC. (4)
* 6,919,370 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof 13 2001
* 2003/0207,936 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof 17 2003
* 2004/0092,428 Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof 24 2003
* 2005/0191,323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof 24 2005
 
SAMSUNG ELECTRO-MECHANICS CO., LTD. (1)
7,414,441 Output buffer circuit 1 2006
 
B. Braun Medical Inc. (1)
7,323,206 Reagents and methods for all-in-one total parenteral nutrition for neonates and infants 6 2004
 
ELAN PHARMA INTERNATIONAL LIMITED (1)
* 2007/0042,049 Nanoparticulate benidipine compositions 4 2006
 
PFIZER PRODUCTS INC. (1)
8,309,129 Nanoparticles comprising a drug, ethylcellulose, and a bile salt 0 2008
 
SIGMOID PHARMA LIMITED (12)
* 2008/0113,031 Minicapsule Formulations 24 2005
* 2008/0020,018 Combination Products 55 2005
* 2006/0018,965 Solid oral dosage form containing seamless microcapsules 8 2005
9,114,071 Oral pharmaceutical composition 0 2008
8,911,777 Pharmaceutical composition of tacrolimus 0 2008
8,535,713 Pharmaceutical cyclosporin compositions 1 2008
* 2010/0203,120 PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS 3 2008
8,951,570 Manufacture of multiple minicapsules 0 2008
9,278,070 Composition comprising oil drops 0 2010
9,220,681 Formulations 0 2013
9,387,179 Pharmaceutical cyclosporin compositions 0 2013
9,320,746 Method for treating intestinal fibrosis 0 2014
 
INSYS DEVELOPMENT COMPANY, INC. (2)
8,628,796 Room-temperature stable dronabinol formulations 0 2005
* 2006/0160,888 Room-temperature stable dronabinol formulations 13 2005
 
ABBOTT PRODUCTS GMBH (6)
* 8,802,087 Pharmaceutical compositions of lipase-containing products, in particular of pancreation 0 2005
* 2005/0250,817 Pharmaceutical compositions of lipase-containing products, in particular of pancreation 5 2005
* 2007/0148,151 PROCESSES FOR THE MANUFACTURE AND USE OF PANCREATIN 27 2006
9,198,871 Delayed release pancreatin compositions 0 2006
* 2007/0148,153 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS 24 2006
* 2009/0130,063 PROCESS FOR SEPARATING AND DETERMINING THE VIRAL LOAD IN A PANCREATIN SAMPLE 2 2008
 
PEPSICO, INC. (2)
* 2008/0098,900 Beverage manufacture using a static mixer 1 2006
* 2011/0086,158 Beverage Manufacture Using a Static Mixer 0 2010
 
PROMETIC PHARMA SMT LIMITED (3)
* 7,745,488 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors 0 2002
* 2006/0128,800 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis 8 2004
* 2004/0147,599 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors 8 2004
 
BEIERSDORF AG (1)
* 7,052,716 Cosmetic and dermatological preparations comprising an effective content of bile acids, their salts and/or their derivatives 0 1999
 
DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER, UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, THE (1)
* 7,169,819 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same 5 2001
 
CANOLIO INC. (1)
* 2004/0037,911 Genital lubricating compositions and uses thereof 9 2003
 
PLIVA, INC. (1)
7,452,552 Pharmaceutical compositions for lipophilic drugs 0 2007
 
Hovid Berhad (1)
* 6,596,306 Drug delivery system:formulation for fat-soluble drugs 2 2000
 
Strides Inc. (1)
* 2004/0033,257 Pharmaceutical formulation in a drug delivery system and process for preparing the same 4 2002
 
CCL PHARMA (1)
* 2004/0052,824 Micellar colloidal pharmaceutical composition containing a lipophilic active principle 23 2003
 
CELLRESIN TECHNOLOGIES, LLC (14)
7,166,671 Grafted cyclodextrin 18 2003
* 2004/0110,901 Grafted cyclodextrin 2 2003
7,385,004 Enhanced lubrication in polyolefin closure with polyolefin grafted cyclodextrin 9 2004
* 2005/0131,119 Enhanced lubrication in polyolefin closure with polyolefin grafted cyclodextrin 1 2004
8,148,466 Amphoteric grafted barrier materials 0 2005
* 2005/0261,426 Amphoteric grafted barrier materials 11 2005
8,501,308 Grafted cyclodextrin 0 2006
7,795,333 Grafted cyclodextrin 2 2006
7,365,123 Grafted cyclodextrin 10 2006
* 2006/0183,856 Grafted cyclodextrin 13 2006
7,605,199 Grafted cyclodextrin 1 2006
* 2006/0205,873 Grafted cyclodextrin 7 2006
8,334,343 Grafted cyclodextrin 0 2007
8,129,450 Articles having a polymer grafted cyclodextrin 5 2007
 
B. BRAUN MELSUNGEN AG (1)
* 2007/0071,777 Oil emulsion for postnatal hormone substitution 4 2004
 
GILEAD PHARMASSET LLC (10)
8,173,621 Nucleoside cyclicphosphates 36 2009
8,716,262 Nucleoside phosphoramidates 8 2009
8,716,263 Synthesis of purine nucleosides 10 2009
8,551,973 Nucleoside analogs 18 2009
8,859,756 Stereoselective synthesis of phosphorus containing actives 8 2011
8,841,275 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections 7 2011
8,759,510 Nucleoside cyclicphosphates 11 2012
9,045,520 Synthesis of purine nucleosides 1 2012
8,957,045 Nucleoside phosphoramidates 1 2013
9,394,331 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections 0 2014
 
NICOX S.A. (3)
7,815,933 Self emulsifying drug delivery system 0 2002
* 2003/0161,846 Self emulsifying drug delivery system 2 2002
* 2010/0266,683 NEW SELF EMULSIFYING DRUG DELIVERY SYSTEM 0 2010
 
NESTEC S.A. (1)
* 2010/0172,875 OIL-IN-WATER EMULSION AND ITS USE FOR THE DELAYED RELEASE OF ACTIVE ELEMENTS 0 2008
 
CHRISTINE ANDERSEN (2)
8,609,143 Morphine polymer release system 10 2008
* 2008/0254,123 Morphine polymer release system 28 2008
 
ABBOTT LABORATORIES (2)
* 2010/0297,194 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER 8 2010
* 2010/0278,921 SOLID ORAL FORMULATION OF ABT-263 8 2010
 
SOFT GEL TECHNOLOGIES, INC. (18)
8,124,072 Solubilized CoQ-10 9 2003
* 2005/0070,611 Solubilized CoQ-10 15 2003
8,105,583 Solubilized CoQ-10 8 2004
* 2005/0069,582 Solubilized CoQ-10 16 2004
8,147,826 Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene 9 2005
8,506,995 Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing 3 2007
* 2008/0003,279 Coenzyme Q10 Formulation and Process Methodology for Soft Gel Capsules Manufacturing 13 2007
* 2008/0089,877 Super Absorption Coenzyme Q10 16 2007
8,343,541 Ubiquinol and alpha lipoic acid compositions 6 2008
* 2008/0226,710 UBIQUINOL AND ALPHA LIPOIC ACID COMPOSITIONS 13 2008
8,658,161 Solubilized CoQ-10 3 2012
8,617,541 Solubilized CoQ-10 3 2012
8,506,859 Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene 3 2012
8,821,925 Ubiquinol and alpha lipoic acid compositions 1 2012
8,865,032 Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene 0 2013
8,932,584 Solubilized CoQ-10 0 2013
8,932,585 Solubilized CoQ-10 0 2014
9,345,672 Ubiquinol and alpha lipoic acid compositions 0 2014
 
TEVA WOMEN'S HEALTH, INC. (2)
8,663,681 Oral dosage forms comprising progesterone and methods of making and using the same 11 2006
* 2006/0275,360 Oral dosage forms comprising progesterone and methods of making and using the same 22 2006
 
RELIANT PHARMACEUTICALS, INC. (4)
8,026,281 Treating metabolic syndrome with fenofibrate 0 2005
* 2006/0083,783 Treating metabolic syndrome with fenofibrate 8 2005
* 2006/0211,762 Omega-3 fatty acids and dyslipidemic agent for lipid therapy 61 2005
* 2006/0211,763 Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof 49 2006
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (2)
6,869,603 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions 1 2002
* 2003/0129,216 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions 0 2002
 
ISIS PHARMACEUTICALS, INC. (2)
* 2003/0176,379 Antisense permeation enhancers 4 2002
8,039,444 Antisense permeation enhancers 0 2006
 
Antares Pharma IPL AG (20)
* 2004/0198,706 Methods and formulations for transdermal or transmucosal application of active agents 40 2004
7,425,340 Permeation enhancing compositions for anticholinergic agents 6 2005
* 2005/0287,194 Permeation enhancing compositions for anticholinergic agents 1 2005
7,335,379 Transdermal pharmaceutical formulation for minimizing skin residues 18 2006
* 2006/0153,905 Transdermal pharmaceutical formulation for minimizing skin residues 10 2006
8,067,399 Method and apparatus for transdermal or transmucosal application of testosterone 3 2006
* 2006/0270,642 Method and apparatus for transdermal or transmucosal application of testosterone 12 2006
7,387,788 Pharmaceutical compositions of nicotine and methods of use thereof 5 2006
7,404,965 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels 6 2006
* 2007/0098,775 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels 6 2006
7,470,433 Formulations for transdermal or transmucosal application 26 2007
* 2007/0166,361 FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION 4 2007
8,268,346 Methods of treating hot flashes with formulations for transdermal or transmucosal application 0 2007
* 2007/0225,379 TRANSDERMAL DELIVERY OF SYSTEMICALLY ACTIVE CENTRAL NERVOUS SYSTEM DRUGS 26 2007
* 2009/0069,364 PHARMACEUTICAL COMPOSITIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND METHODS OF USE THEREOF 6 2008
8,980,290 Transdermal compositions for anticholinergic agents 0 2009
8,980,309 Transdermal testosterone formulation for minimizing skin residues 0 2011
8,338,400 Methods and apparatus for transdermal or transmucosal application of testosterone 0 2011
8,652,491 Transdermal compositions for anticholinergic agents 0 2012
8,647,665 Methods of treating hot flashes with formulations for transdermal or transmucosal application 0 2012
 
AMERICAN SYMBOLIC, LLC (1)
* 2008/0311,093 STEM CELL SECRETIONS AND RELATED METHODS 7 2007
 
RTP Pharma, Inc. (2)
6,979,456 Anticancer compositions 27 1999
* 6,726,919 Injectable dispersion of propofol 18 2001
 
NAIDU LP (8)
7,956,031 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy 14 2006
* 2006/0269,535 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy 8 2006
* 8,021,659 Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof 8 2006
* 2007/0253,941 Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof 22 2006
8,476,223 Metallo-lactoferrin-coenzyme compositions to improve sleep patterns 0 2011
8,968,726 Lactoferrin and angiogenin compositions and uses thereof 0 2011
9,283,253 Metallo-lactoferrin-coenzyme compositions for detoxification support 0 2013
9,180,148 Metallo-lactoferrin-coenzyme compositions and methods for weight management 0 2013
 
DEBIOPHARM INTERNATIONAL SA (17)
7,790,709 Heterocyclic compounds, methods of making them and their use in therapy 5 2003
* 2006/0183,908 Heterocyclic compounds, methods of making them and their use in therapy 16 2003
8,450,307 Therapeutic agents, and methods of making and using the same 2 2005
7,879,872 Compositions comprising multiple bioactive agents, and methods of using the same 4 2005
7,741,339 Fab I inhibitors 6 2007
* 2009/0221,699 Fab I Inhibitors 8 2007
8,318,720 Acrylamide derivatives as Fab I inhibitors 2 2007
* 2010/0130,470 ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS 8 2007
8,263,613 Salts, prodrugs and polymorphs of fab I inhibitors 2 2008
* 2009/0042,927 Salts, Prodrugs and Polymorphs of Fab I Inhibitors 10 2008
7,790,716 Fab I inhibitors 9 2009
8,153,652 Fab I inhibitors 2 2010
* 2011/0098,277 Fab I Inhibitors 1 2010
8,173,646 FAB I inhibitors 2 2010
* 2011/0190,283 Fab I Inhibitors 1 2010
8,895,545 Acrylamide derivatives as Fab I inhibitors 0 2012
8,901,105 Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide 0 2013
 
ARCHIMEDES DEVELOPMENT LIMITED (1)
* 2001/0051,613 Novel formulations of fexofenadine 13 2001
 
SANTEN PHARMACEUTICAL CO., LTD. (14)
8,637,070 Rapamycin formulations and methods of their use 1 2006
8,492,400 Stable formulations, and methods of their preparation and use 0 2007
* 2007/0203,173 Stable formulations, and methods of their preparation and use 21 2007
8,222,271 Formulations and methods for vascular permeability-related diseases or conditions 1 2007
8,663,639 Formulations for treating ocular diseases and conditions 0 2008
* 2009/0324,687 TRANSSCLERAL DELIVERY 17 2009
* 2009/0324,689 TRANSSCLERAL DELIVERY 17 2009
* 2009/0324,690 TRANSSCLERAL DELIVERY 17 2009
8,367,097 Liquid formulations for treatment of diseases or conditions 5 2010
8,486,960 Formulations and methods for vascular permeability-related diseases or conditions 0 2012
8,927,005 Liquid formulations for treatment of diseases or conditions 1 2013
8,658,667 Stable formulations, and methods of their preparation and use 0 2013
9,387,165 Rapamycin formulations and methods of their use 0 2014
9,381,153 Liquid formulations for treatment of diseases or conditions 0 2014
 
PAUL ROYALTY FUND, L.P. (2)
7,097,849 Injectable aqueous dispersions of propofol 3 1999
7,041,705 Injectable aqueous dispersions of propofol 6 2001
 
CARGILL, INCORPORATED (2)
* 6,623,780 Aqueous dispersible sterol product 16 2002
* 2004/0013,708 Aqueous dispersible steryl ester compositions 3 2003
 
DRUGTECH CORPORATION (6)
* 2005/0171,177 Method of treatment of Candida isolates 0 2004
* 2005/0095,245 Pharmaceutical delivery system 9 2004
* 2006/0140,990 Composition for topical treatment of mixed vaginal infections 37 2006
* 2007/0110,805 Modified-release pharmaceutical compositions 5 2006
* 2007/0224,226 COMPOSITION AND METHOD OF USE THEREOF 2 2006
* 2008/0161,376 METHOD OF TREATING CANDIDA ISOLATES 0 2007
 
BANNER LIFE SCIENCES LLC (1)
* 2007/0098,786 ENTERIC VALPROIC ACID 0 2006
 
BANK OF AMERICA, N.A., AS SUCCESSOR AGENT (1)
9,173,419 Method of improving animal feeds using hydrolyzed lecithins 0 2013
 
Clarus Therapeutics, Inc. (6)
8,241,664 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same 16 2006
* 2008/0317,844 Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Compositions Comprising Same 24 2006
8,492,369 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same 1 2010
8,778,916 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same 0 2012
8,778,917 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same 0 2013
8,828,428 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same 0 2014
 
Schering-Plough Kabushiki Kaisha (1)
* 2008/0064,713 Dry Syrup Containing Loratadine 1 2004
 
BESINS HEALTHCARE INC. (2)
9,132,089 Pharmaceutical composition and method for treating hypogonadism 0 2013
9,125,816 Pharmaceutical composition and method for treating hypogonadism 0 2013
 
Supernus Pharmaceuticals, Inc. (4)
* 7,011,846 Oral capsule formulation with increased physical stability 16 2002
* 2003/0124,182 Oral capsule formulation with increased physical stability 13 2002
* 7,022,337 Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect 8 2003
* 2004/0110,842 Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect 0 2003
 
NOVACEA, INC. (4)
* 2003/0191,093 Pharmaceutical compositions comprising active vitamin D compounds 1 2002
* 2005/0101,576 Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes 12 2004
* 2005/0026,877 Pharmaceutical compositions comprising active vitamin D compounds 0 2004
* 2005/0020,546 Pharmaceutical compositions comprising active vitamin D compounds 1 2004
 
PHYSICA PHARMA (1)
* 2008/0311,160 Clear Pharmaceutical Aqueous Emulsion Composition Which Comprises Propofol and Process for Preparing this Composition 0 2005
 
SOV THERAPEUTICS (1)
* 2011/0160,168 MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS 2 2010
 
NICOX SCIENCE IRELAND (1)
7,736,666 Self emulsifying drug delivery system 0 2001
 
TEIKOKU PHARMA USA, INC. (2)
8,940,786 Non-aqueous taxane nanodispersion formulations and methods of using the same 1 2013
9,308,195 Non-aqueous taxane formulations and methods of using the same 0 2014
 
COGNIS IP MANAGEMENT GMBH (1)
* 2011/0281,810 Composition 1 2011
 
WATSON LABORATORIES, INC. (5)
7,988,995 Pharmaceutical compositions for lipophilic drugs 7 2002
8,119,157 Pharmaceutical compositions for lipophilic drugs 0 2006
* 2006/0188,561 Pharmaceutical compositions for lipophilic drugs 1 2006
7,799,340 Pharmaceutical compositions for lipophilic drugs 7 2007
* 2007/0259,810 PHARMACEUTICAL COMPOSITIONS FOR LIPOPHILIC DRUGS 0 2007
 
WYETH (1)
* 2005/0152,968 Microemulsions for pharmaceutical compositions 9 2005
 
Galephar Pharmaceutical Research, Inc. (7)
* 7,435,427 Pharmaceutical semi-solid composition of isotretinoin 0 2001
* 2004/0009,225 Pharmaceutical semi-solid composition of isotretinoin 4 2003
8,367,102 Pharmaceutical semi-solid composition of isotretinoin 0 2007
* 2008/0171,084 Pharmaceutical semi-sold composition of isotretinoin 0 2007
8,952,064 Pharmaceutical semi-solid composition of isotretinoin 0 2012
9,089,534 Pharmaceutical semi-solid composition of isotretinoin 0 2012
9,078,925 Pharmaceutical semi-solid composition of isotretinoin 0 2013
 
VIRUN, INC. (8)
8,765,661 Compositions containing non-polar compounds 2 2009
8,282,977 Compositions containing non-polar compounds 5 2009
* 2009/0297,665 Compositions containing non-polar compounds 11 2009
8,337,931 Compositions containing non-polar compounds 4 2009
9,320,295 Compositions containing non-polar compounds 0 2011
* 2011/0236,364 Compositions containing non-polar compounds 7 2011
8,741,373 Compositions containing non-polar compounds 17 2011
9,351,517 Formulations of water-soluble derivatives of vitamin E and compositions containing same 0 2014
 
WYETH LLC (1)
* 2009/0155,353 MICROEMULSIONS FOR PHARMACEUTICAL COMPOSITIONS 0 2009
 
Ivax Pharmaceuticals S.R.O. (2)
* 8,673,351 Crystallization inhibitor and its use in gelatin capsules 0 2006
* 2011/0020,438 Crystallization Inhibitor and Its Use in Gelatin Capsules 1 2006
 
CEPHALON, INC. (10)
7,297,346 Pharmaceutical formulations of modafinil 5 2002
* 2003/0022,940 Novel pharmaceutical formulations of modafinil 6 2002
7,229,644 Pharmaceutical formulations of modafinil 4 2002
* 2003/0220,403 Novel pharmaceutical formulations of modafinil 6 2002
* 2008/0058,424 Novel pharmaceutical formulations of modafinil 1 2007
8,268,892 Pharmaceutical formulations of modafinil 1 2008
* 2008/0207,761 Pharmaceutical formulations of modafinil 0 2008
* 2010/0129,444 Novel Pharmaceutical Formulations of Modafinil 0 2010
8,859,621 Pharmaceutical formulations of modafinil 0 2012
8,686,047 Pharmaceutical formulations of modafinil 0 2012
 
GLOBAL ACCESS, INC. (1)
* 2002/0119,237 Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis 7 2001
 
CORTENDO AB (PUBL) (1)
* 2005/0013,834 Pharmaceutical formulations comprising ketoconazole 1 2004
 
LIPOCINE INC. (11)
* 6,720,001 Emulsion compositions for polyfunctional active ingredients 113 1999
* 2002/0107,265 EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS 12 1999
* 6,761,903 Clear oil-containing pharmaceutical compositions containing a therapeutic agent 82 2001
* 2003/0104,048 Pharmaceutical dosage forms for highly hydrophilic materials 117 2002
* 2006/0034,937 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions 42 2005
* 2010/0136,105 PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS 32 2009
9,034,858 High-strength testosterone undecanoate compositions 2 2012
8,778,922 Steroidal compositions 3 2012
8,865,695 Steroidal compositions 2 2014
9,358,241 High-strength testosterone undecanoate compositions 0 2014
9,205,057 High-strength testosterone undecanoate compositions 1 2015
 
HILL DERMACEUTICALS (3)
7,544,674 Topical skin care composition 3 2002
* 2004/0081,668 Topical skin care composition 0 2002
* 2005/0101,580 Topical skin care composition 6 2004
 
BEND RESEARCH, INC. (3)
8,703,204 Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer 25 2008
8,974,827 Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer 0 2008
9,233,078 Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer 0 2008
 
JUPITAR PTY LTD (1)
* 2004/0167,034 Emulsion and dispersion formulations and method 7 2004
 
Otsuka Pharmaceutical Co., Ltd. (4)
* 7,825,130 PTEN inhibitor or Maxi-K channels opener 1 2004
* 2006/0154,963 Pten inhibitor or maxi-k channels opener 2 2004
8,329,731 PTEN inhibitor or Maxi-K channels opener 0 2009
8,653,104 PTEN inhibitor or Maxi-K channels opener 0 2012
 
HILL DERMACEUTICALS, INC. (3)
7,169,401 Topical skin care composition containing refined peanut oil 2 2004
* 2005/0053,635 Topical skin care composition containing refined peanut oil 0 2004
* 2007/0140,999 TOPICAL SKIN CARE COMPOSITION CONTAINING REFINED PEANUT OIL 33 2007
 
STRIDES ARCOLAB LIMITED (1)
* 2006/0286,164 Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same 0 2004
 
TOPPAN PRINTING CO., LTD. (1)
* 2006/0183,257 Method for analyzing electrolytic copper plating solution, and analyzing device therefor and production method for semi-conductor product 1 2004
 
GP Pharm, S.A. (1)
* 2011/0130,446 INJECTABLE TAXANE PHARMACEUTICAL COMPOSITION 2 2009
 
EMS S.A. (2)
* 9,278,065 Delivery systems for solubilising water-insoluble pharmaceutical active ingredients 0 2008
* 2012/0177,692 DELIVERY SYSTEMS FOR SOLUBILISING WATER-INSOLUBLE PHARMACEUTICAL ACTIVE INGREDIENTS 0 2008
 
CANON KABUSHIKI KAISHA (3)
* 2007/0248,571 Ejection Liquid, Ejection Method, Method for Forming Liquid Droplets, Liquid Ejection Cartridge and Ejection Apparatus 6 2005
8,833,363 Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus 0 2010
* 2011/0079,223 EJECTION LIQUID, EJECTION METHOD, METHOD FOR FORMING LIQUID DROPLETS, LIQUID EJECTION CARTRIDGE AND EJECTION APPARATUS 0 2010
 
ARCHER-DANIELS-MIDLAND COMPANY (1)
* 2003/0228,395 Isotropic transparent structured fluids 3 2003
 
INTOCELL DISTRIBUTORS, LLC (1)
* 2010/0041,622 Compositions containing aminoalkanes and aminoalkane derivatives 17 2009
 
Intelgenx Corp. (3)
8,735,374 Oral mucoadhesive dosage form 0 2010
* 2011/0028,431 ORAL MUCOADHESIVE DOSAGE FORM 0 2010
* 2011/0136,815 SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME 1 2010
 
SANGUIBIOTECH GMBH (1)
* 2005/0232,953 Microemulsions having a binary phase differentiability and active substance differentiability, the production thereof and their use, particularly for the topical supply of oxygen 8 2004
 
LEO PHARMA A/S (1)
* 2012/0322,776 CUTANEOUS COMPOSITION COMPRISING VITAMIN D ANALOGUE AND A MIXTURE OF SOLVENT AND SURFACTANTS 0 2010
 
CJ CORPORATION (1)
* 2005/0118,254 Microemulsion preconcentrate 26 2004
 
INFIRST HEALTHCARE LIMITED (7)
8,895,536 Compositions and methods for treating chronic inflammation and inflammatory diseases 9 2012
8,895,537 Compositions and methods for treating cardiovascular diseases 3 2012
9,308,213 Solid solution compositions and use in chronic inflammation 0 2014
9,271,950 Compositions for treating chronic inflammation and inflammatory diseases 0 2014
9,265,742 Compositions and methods for treating inflammatory pain 0 2014
9,381,180 Compositions and methods for treating chronic inflammation and inflammatory diseases 0 2014
9,326,958 Compositions for treating chronic inflammation and inflammatory diseases 0 2014
 
BIOMAX, INC. (1)
* 2004/0110,667 Carrier system for cyclosporin pharmaceutical compositions 2 2003
 
GENERAL TOPICS S.r.l. (1)
* 7,169,811 Composition based on ethyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhea and acne 0 2002
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,559,139 Combination chemotherapy 6 2000
 
Ronald G. Udell (1)
* 2006/0013,888 Solubilized CoQ-10 13 2005
 
PBM Pharmaceuticals, Inc. (3)
8,075,910 Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions 2 2005
* 8,173,160 Compositions comprising edible oils and vitamins and/or minerals and methods for making the compositions 1 2005
* 2008/0274,175 Compositions Comprising Edible Oils and Vitamins and/or Minerals and Methods for Making the Compositions 5 2005
 
AVENTIS PHARMA S.A. (2)
* 2005/0025,792 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids 2 2004
* 2009/0069,411 SELF-EMULSIFYING AND SELF-MICROEMULSIFYING FORMULATIONS FOR THE ORAL ADMINISTRATION OF TAXOIDS 0 2008
 
ALLERGAN, INC. (33)
6,635,654 Ophthalmic compositions containing loratadine 1 2003
* 7,297,679 Cyclosporin compositions 17 2005
7,276,476 Cyclosporin compositions 16 2005
7,202,209 Cyclosporin compositions 19 2005
* 2007/0015,710 Cyclosporin compositions 4 2005
* 2007/0015,692 Cyclosporin compositions 5 2005
* 2007/0015,691 Cyclosporin compositions 12 2005
* 2007/0015,693 Cyclosporin compositions 5 2005
* 2007/0015,690 Cyclosporin compositions 0 2005
7,501,393 Pharmaceutical compositions comprising cyclosporins 14 2005
* 2007/0027,072 PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLOSPORINS 8 2005
7,288,520 Cyclosporin compositions 26 2005
* 2007/0015,694 Cyclosporin compositions 7 2005
* 8,288,348 Cyclosporin compositions 12 2006
7,745,400 Prevention and treatment of ocular side effects with a cyclosporin 3 2006
* 2007/0167,358 PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN 3 2006
8,536,134 Cyclosporin compositions 3 2007
8,211,855 Cyclosporin compositions 13 2007
8,575,108 Cyclosporin compositions 1 2007
* 2008/0070,834 Cyclosporin Compositions 11 2007
8,906,861 Pharmaceutical compositions comprising cyclosporins 0 2009
8,501,174 Prevention and treatment of ocular side effects with a cyclosporin 0 2010
* 2010/0266,622 PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN 0 2010
8,563,518 Cyclosporin compositions 3 2012
8,685,930 Methods of providing therapeutic effects using cyclosporin components 1 2013
8,648,048 Methods of providing therapeutic effects using cyclosporin components 1 2013
8,642,556 Methods of providing therapeutic effects using cyclosporin components 1 2013
8,633,162 Methods of providing therapeutic effects using cyclosporin components 1 2013
8,629,111 Methods of providing therapeutic effects using cyclosporin components 1 2013
8,969,306 Cyclosporin compositions 0 2013
9,101,574 Cyclosporin compositions 1 2013
8,969,307 Cyclosporin compositions 0 2013
9,248,191 Methods of providing therapeutic effects using cyclosporin components 0 2014
 
CHIASMA, INC. (1)
* 2005/0058,702 Compositions capable of facilitating penetration across a biological barrier 17 2003
 
PHARMACIA CORPORATION (1)
* 2005/0187,278 Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors 1 2004
 
NITTO DENKO CORPORATION (1)
8,003,621 Drug carriers 5 2008
 
JAGOTEC AG (1)
* 2004/0151,776 Novel compositions 0 2003
 
CYDEX PHARMACEUTICALS, INC. (4)
6,869,939 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin 3 2002
* 2005/0250,738 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin 10 2005
* 2007/0020,298 Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid 4 2006
* 2009/0312,724 Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions 16 2009
 
Borkan, Lionel (1)
* 8,287,904 Stable soft capsule dosage form for acetylsalicylic acid 0 2010
 
KEMIN INDUSTRIES, INC. (2)
8,603,568 Hydrolyzed lecithin product to improve digestibility 1 2011
* 2011/0177,194 Hydrolyzed Lecithin Product to Improve Digestibility 0 2011
 
ZOETIS SERVICES LLC (4)
* 7,687,471 Benzimidazole non-aqueous compositions 0 2006
* 2007/0128,239 Benzimidazole non-aqueous compositions 1 2006
9,283,176 Benzimidazole anthelmintic compositions 0 2009
* 2010/0087,497 Benzimidazole Anthelmintic Compositions 0 2009
 
DEXCEL LTD (2)
7,026,290 Dispersible concentrate for the delivery of cyclosprin 7 1999
7,732,404 Pro-nanodispersion for the delivery of cyclosporin 0 2006
 
UNIVERSITI PUTRA MALAYSIA (2)
* 8,598,236 Emulsion system derived from engkabang fat esters 0 2010
* 2012/0165,415 EMULSION SYSTEM DERIVES FROM ENGKABANG FAT ESTERS 0 2010
 
Unimed Pharmaceuticals, LLC (8)
8,466,136 Testosterone gel and method of use 2 2011
8,466,137 Testosterone gel and method of use 2 2011
8,486,925 Testosterone gel and method of use 2 2011
8,466,138 Testosterone gel and method of use 3 2011
8,759,329 Testosterone gel and method of use 0 2013
8,754,070 Testosterone gel and method of use 0 2013
8,741,881 Testosterone gel and method of use 0 2013
8,729,057 Testosterone gel and method of use 0 2013
 
SANOFI (1)
* 6,528,539 Stable formulation containing fumagillin 2 2001
 
HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (1)
* 2004/0258,623 Insulin-containing oral spray and the preparation method thereof 1 2004
 
LYFJATHROUN HF. (3)
6,855,332 Absorption promoting agent 8 2002
* 2004/0005,275 Absorption promoting agent 7 2002
* 2005/0063,940 Bioadhesive agent 0 2004
 
LODERS CROKLAAN USA LLC (3)
* 7,582,317 Food supplements comprising, as a health component, sargahydroquinoic acid or derivative thereof 0 2002
* 2003/0129,294 Blends comprising a substituted fatty acid or a derivative thereof 5 2002
* 2010/0029,766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof 1 2009
 
SEMBIOSYS GENETICS INC. (1)
* 2008/0241,082 Method for the Preparation of Cosmetic Emulsion 3 2005
 
RPG Life Sciences Limited (1)
* 7,056,530 Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities 0 2000
 
Gilead Pharmassel LLC (1)
8,563,530 Purine nucleoside phosphoramidate 13 2011
 
ARENA PHARMACEUTICALS, INC. (4)
8,362,248 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto 1 2006
* 2007/0167,473 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto 20 2006
8,410,119 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto 1 2009
8,933,083 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia 0 2012
 
STERIX LIMITED (1)
* 2004/0147,494 Use 1 2004
 
ABBVIE INC. (6)
8,728,516 Stabilized lipid formulation of apoptosis promoter 0 2010
8,362,013 Salt of ABT-263 and solid-state forms thereof 0 2010
* 2010/0305,125 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF 3 2010
* 2010/0311,751 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT 4 2010
8,927,009 ABT-263 capsule 0 2010
8,691,878 Solid pharmaceutical dosage form 1 2012
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
* 2007/0129,340 Ed-71 preparation 1 2005
 
NOSTRUM PHARMACEUTICALS, INC. (2)
7,897,179 Pharmaceutical composition containing water soluble drug 5 2004
8,906,419 Pharmaceutical composition containing water soluble drug 0 2011
 
HORIZON PHARMA AG (3)
* 2010/0222,312 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA 1 2010
* 2010/0196,427 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE 1 2010
8,920,838 Delayed-release glucocorticoid treatment of rheumatoid disease 0 2013
 
GALDERMA S.A. (5)
7,915,243 Topical skin care composition 3 2004
7,939,516 Topical skin care composition 2 2007
8,247,395 Topical skin care composition 0 2011
8,653,053 Topical skin care composition 0 2012
9,333,172 Topical skin care composition 0 2014
 
EASTMAN CHEMICAL COMPANY (1)
* 2006/0240,051 Eutectic blends containing a water soluble vitamin derivative 1 2005
 
EGALET LTD. (13)
8,877,241 Morphine controlled release system 2 2004
* 8,298,581 Matrix compositions for controlled delivery of drug substances 1 2004
* 2007/0042,044 Matrix compositions for controlled delivery of drug substances 26 2004
* 2010/0291,205 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MITIGATING RISK OF ALCOHOL INDUCED DOSE DUMPING OR DRUG ABUSE 13 2008
8,617,605 Polymer release system 7 2008
* 2008/0254,122 Polymer release system 10 2008
* 2010/0166,866 MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES 24 2009
9,005,660 Immediate release composition resistant to abuse by intake of alcohol 2 2010
9,023,394 Formulations and methods for the controlled release of active drug substances 1 2013
8,808,745 Morphine polymer release system 5 2013
9,044,402 Abuse-deterrent pharmaceutical compositions for controlled release 1 2014
9,375,428 Morphine controlled release system 0 2014
9,358,295 Immediate release composition resistant to abuse by intake of alcohol 0 2015
* Cited By Examiner